Skip to content Skip to sidebar Skip to footer

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Rhythm Biosciences (ASX: RHY) may finally be turning the corner. The company has secured NHS expertise to support its ColoSTAT bowel cancer blood test launch in the UK, while a…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

The tables have turned, and shareholders face a key decision as the 10 December deadline approaches. Mayne Pharma (ASX: MYX) has turned the tables on US suitor Cosette Pharmaceuticals, issuing…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks IPOs

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in an otherwise quiet year for ASX biotech debuts. Unlike most…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia's first-in-human head and neck cancer imaging study. The ground-breaking study will recruit 50 patients at the St…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks Uncategorized

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Epiminder (ASX: EPI) made its ASX debut on Monday after raising $125 million at $1.50 per share, giving the company a market capitalisation of approximately $325 million. The Melbourne-based medtech…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

Paragon Care (ASX: PGC) is betting big on Asia. The healthcare distributor, currently trading near its 52-week lows around $0.29, has struck a $70 million deal to acquire Haju Medical,…

ByUjjwal Maheshwari

the Kick-ass Multipurpose WordPress Theme

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

PLS Group (ASX:PLS) Hits Record High on...

Narryer Metals (ASX:NYM) Tim Goyder Back...

Sovereign Metals (ASX:SVM) DFS lands,$2....

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here